Circa Pharmaceuticals
Executive Summary
Signs an agreement with Hi-Tech Pharmacal to "develop and jointly market four generic prescription solutions," the firms announced March 30. Circa, which recently changed its name from Bolar, will contribute $1.2 mil. towards the development of the four drugs, while Hi-Tech submits the ANDAs and retains manufacturing rights.